Phase I/II study of stereotactic body radiation therapy (SBRT) to metastatic lesions in the liver or lung in combination with monoclonal antibody to OX40 in patients with progressive metastatic breast cancer (mBC) after systemic therapy.

@inproceedings{Crittenden2015PhaseIS,
  title={Phase I/II study of stereotactic body radiation therapy (SBRT) to metastatic lesions in the liver or lung in combination with monoclonal antibody to OX40 in patients with progressive metastatic breast cancer (mBC) after systemic therapy.},
  author={Marka R. Crittenden and Alison K Conlin and Nicole Moxon and Brendan D. Curti},
  year={2015}
}
TPS3103 Background: Focal radiation mediates tumor regression not only through direct cell killing, but also by influencing adaptive immune responses. We and others have investigated pre-clinical murine tumor models using the combination of high dose per fraction radiation (SBRT) given in conjunction with T-cell checkpoint and co-stimulatory molecules. For instance, in established 3LL tumor in C57BL/6 mice, the combination of radiation (3 doses of 20 Gy over 10 days) followed by an agonistic… CONTINUE READING